抗口腔支原体,精氨酸支原体单克隆抗体的制备及其应用方法的初步研究

用口腔支原体，精氨酸支原体抗原免疫ＢＡＬＢ／ｃ小鼠，取其脾细胞，与小鼠骨髓瘤细胞（Ｓｐ２／０）融合，获得了７株稳定分泌抗口腔支原体单克隆抗体（ＭｃＡｂ），２株分泌抗精氨酸支原体ＭｃＡｂ的杂交瘤细胞株。间接ＥＬＩＳＡ测定其抗体效价可达１：１０＾３～１：１０＾７，９株ＭｃＡｂ中１株为ＩｇＧ２ａ，其余均为ＩｇＧ１。初步建立了ＥＬＩＳＡ检测支原体的方法。     

抗淋球菌PIA单克隆抗体的制备和应用分析

用淋球菌全菌体免疫ＢＡＬＢ／ｃ小鼠，取脾细胞与Ｓｐ２／０骨髓瘤细胞融合，以纯化ＰＩＡ做ＥＬＩＳＡ间接法筛选，获得５株稳定分泌抗ＰＩＡ的ＭｃＡｂ的杂交瘤细胞株。５株ＭｃＡｂ中３株为ＩｇＭ类（２Ｈ１１，４Ｈ８，４Ｅ１０），另２株分别为ＩｇＧ１（１Ｃ２）和ＩｇＧ２ｂ（５Ａ５）亚类。２Ｈ１１和１Ｃ２为高亲和力抗体，１Ｃ２与５Ａ５识别的抗原表位相同。Ｗｅｓｔｅｒｎ ｂｌｏｔｔｉｎｇ试验表明，５株ＭｃＡｂ均能     

抗淋球菌PIA单克隆抗体的制备和应用分析

用淋球菌全菌体免疫ＢＡＬＢ／ｃ小鼠，取脾细胞与Ｓｐ２／０骨髓瘤细胞融合，以纯化ＰＩＡ做ＥＬＩＳＡ间接法筛选，获得５株稳定分泌抗ＰＩＡ的ＭｃＡｂ的杂交瘤细胞株。５株ＭｃＡｂ中３株为ＩｇＭ类（２Ｈ１１，４Ｈ８，４Ｅ１０），另２株分别为ＩｇＧ１（１Ｃ２）和ＩｇＧ２ｂ（５Ａ５）亚类。２Ｈ１１和１Ｃ２为高亲和力抗体，１Ｃ２与５Ａ５识别的抗原表位相同。Ｗｅｓｔｅｒｎｂｌｏｔｔｉｎｇ试验表明，５株ＭｃＡｂ均能从复杂的淋球菌菌体崩解物中特异地识别分子量为３５ＫＤａ的ＰＩＡ抗原，与淋球菌ＰＩＢ无交叉反应。     

抗人Ig轻链系列单抗的研制：Ⅲ抗人Ig游离λ型轻链共同抗原决定…

用多例提纯的ＢＪ－λ混合免疫ＢＡＬＢ／ｃ小鼠的脾细胞与骨髓瘤细胞Ｓｐ２／０融合，获得３株稳定分泌抗人Ｉｇ游离λ链ＭｃＡｂ的杂交瘤细胞株（ＡＨλＤ８、ＡＨλ１Ｃ１和ＡＨλ２Ｃｌ）。它们分泌的ＭｃＡｂ均能与我室所有１７例ＢＪ－λ起强反应，但不与结合的λ型轻链及Ｋ型轻链反应，表明这３株ＭｃＡｂ可能是抗人Ｉｇ游离λ链共同抗原决定簇的。３株ＭｃＡｂ均属小鼠ＩｇＧ１亚类。添加ＥＬＩＳＡ表明它们识别相同的表位。     

重组人红细胞生成素单克隆抗体的制备

本文应用常规淋巴细胞杂交瘤技术制备了４株能稳定分泌抗人重组红细胞生成素（ｒＨｕＥＰＯ）单克隆抗体（ＭｃＡｂ）的小鼠杂交瘤细胞系ＢⅡ１Ｂ５、ＤⅡ６Ｂ９、ＭⅡ１Ｈ４和ＧＩ３Ｅ７。用鼠单克隆抗体分型试剂盒鉴定，其分泌的ＭｃＡｂ的类分别是ＩｇＭ、ＩｇＭ、ＩｇＧ１和ＩｇＧ２ａ。间接ＥＬＩＳＡ法测定细胞上清的效价为１×１０－２～１．２５×１０－４，腹水效价为１×１０－２～１×１０－８。培养上清经ＥＬＩＳＡ鉴定，与ＩＬ－２、ＧＭ－ＣＳＦ、ＩＦＮ－α等细胞因子均无交叉反应，只与ｒＨｕＥＰＯ特异性结合。     

分泌抗金黄色葡萄球菌C1型肠毒素杂交瘤细胞系的建立及初步应用

应用常规方法建立了３株稳定分泌抗金黄色葡萄球菌Ｃ１型肠毒素（ＳＥＣ１）单克隆抗体（ＭｃＡｂ）的小鼠杂交瘤细胞系Ｂ３、Ｃ４和Ｇ８。其中Ｂ３和Ｃ４均为ＩｇＧ１（ｋ），Ｇ８为ＩｇＧ２ａ（ｋ）。Ｂ３和Ｇ８与ＳＥＡ、ＳＥＢ及ＳＥＤ均无交叉反应；Ｃ４虽与ＳＥＡ和ＳＥＤ无交叉反应，但与ＳＥＢ有交叉反应。间接ＥＬＩＳＡ测定小鼠腹水效价为１０－５～１０－８。应用识别不同表位的ＭｃＡｂ建立了双ＭｃＡｂ夹心ＥＬＩＳＡ法检测ＳＥＣ１，敏感性可达１ｎｇ／ｍｌ。     

分泌抗rHuIL－6McAb杂交瘤细胞系的建立及其应用研究

应用常规方法建立了４株稳定分泌抗重组人ＩＬ－６（ｒＨｕＩＬ－６）单克隆抗体（ＭｃＡｂ）的小鼠杂交瘤细胞系１Ｈ３、２Ａ１０、３Ａ３和４Ｂ１。其中，１Ｈ３为ＩｇＧ２ｂ（ｋ），２Ａ１０为ＩｇＧ１（ｋ），３Ａ３和４Ｂ１为ＩｇＧ２ａ（ｋ）。４株ＭｃＡｂ特异性强，与细胞因子ＩＬ－１β、ＩＬ－３、ＩＬ－８、ＴＮＦ－α、ＧＭ－ＳＣＦ、ＩＣＡＭ－１，以及受体菌菌体蛋白成分均无交叉反应。间接ＥＬＩＳＡ测定小鼠腹水ＭｃＡｂ效价为１０（－６）～１０（－８）。应用识别不同表位的ＭｃＡｂ建立了双抗体夹心ＥＬＩＳＡ法检测ＩＬ－６，敏感性为１００ｐｇ／ｍｌ。初步应用表明可用于临床标本的检测。     

分泌抗金黄色葡萄球菌C1型肠毒素杂交瘤细胞系的建立及初步应用

应用常规方法建立了３株稳定分泌抗金黄色葡萄球菌Ｃ１型肠毒素（ＳＥＣ１）单克隆抗体（ＭｃＡｂ）的小鼠杂交瘤细胞系Ｂ３、Ｃ４和Ｇ８。其中Ｂ３和Ｃ４均为ＩｇＧ１（ｋ），Ｇ８为ＩｇＧ２ａ（ｋ）。Ｂ３和Ｇ８与ＳＥＡ，ＳＥＢ及ＳＥＤ均无交叉反应；Ｃ４虽与ＳＥＡ和ＳＥＤ无交叉反应，但与ＳＥＢ有交叉反应。间接ＥＬＩＳＡ测定小鼠腹水效价为１０＾－５～１０＾－８。应用识别不同表位的ＭｃＡｂ建立了双ＭｃＡｂ夹心ＥＬＩＳ     

分泌抗rHuIL—6McAb杂交瘤细胞系的建立及其应用研究

应用常规方法建立了４株稳定分泌抗重组人ＩＬ－６（ｒＨｕＩＬ－６）单克隆抗体（ＭｃＡｂ）小鼠杂交瘤细胞系１Ｈ３、２Ａ１０、３Ａ３和４Ｂ１。其中，１Ｈ３为ＩｇＧ２ｂ（Ｋ），２Ａ１０为ＩｇＧ１（Ｋ），３Ａ３和４Ｂ１为ＩｇＧ２ａ（Ｋ）。４株ＭｃＡｂ特异性强，与细胞因子ＩＬ－１β、ＩＬ－３、ＩＬ－８、ＴＮＦ－α、ＧＭ－ＳＣＦ、ＩＣＡＭ－１，以及受体菌菌体蛋白成分均无交叉反应。间接ＥＬＩＳＡ测定小鼠腹水ＭｃＡ     

人心肌肌钙蛋白T单克隆抗体的研制及鉴定

以人心肌肌钙蛋白Ｔ（ｃＴｎＴ）为抗原，采用脾内免疫法，免疫ＢＡＬＢ／ｃ小鼠，取其脾淋巴细胞与小鼠Ｓｐ２／０细胞融合，经间接ＥＬＩＳＡ法筛选，三次克隆化后获得５株能稳定分泌抗ｃＴｎＴ单克隆抗体（ＭｃＡｂ）的杂交瘤细胞Ｇ３、Ｇ８、Ｇ１０、Ａ５和Ａ７。免疫球蛋白亚类鉴定其中１株为ＩｇＧ２ａ，４株为ＩｇＭ。染色体数目９２～１１０条。将Ｇ３、Ｇ８、Ｇ１０、Ａ５的单克隆抗体腹水做１：１００稀释与ＬＤＨ、ＣＫ、ＣＫＭＢ和ＧＯＴ等心肌酶均无交叉反应。５株ＭｃＡｂ的腹水效价为３．２×１０－６～１．６×１０－７。ＭｃＡｂ相加试验表明，Ａ５和Ｇ３可识别不同的抗原表位。     

4种抗支原体单克隆抗体免疫学特性的研究

为了有效地控制细胞质量、我们从1987年开始、相继建立了抗口腔支原体(M.orale),精氨酸支原体(M.arginini),猪鼻支原体(M.hyorhinis).和莱氏无胆甾原体(A.laidlawii)的杂交瘤细胞系共20株。并用IFA法、BA法或APAAP法对单克隆抗体进行了检测和鉴定。单克隆抗体(McAb)亚类鉴定结果:8株为IgG1,2株为IgG2b,其余10株为IgM。抗体效价测定大多数在4000～8 000之间。利用支原体纯培养的菌落进行了IFA染色试验,封闭试验,生长抑制试验和免疫电镜检查,均证实了它们的特异性,并获得2株对同属支原体有抗原交叉的McAb(3D1和3A11)。利用上述McAb检测实验室常用细胞的支原体污染,较常规法和DNA荧光染色法简便,快速,特异性较高。     

金葡菌肠毒素C2的单克隆抗体制备、鉴定及初步应用

目的：制备抗金葡菌肠毒素C2（SEC2）的单克隆抗体（MeAb），并建立SEC2检测方法。方法：以金葡菌培养液中纯化的SEC2为抗原，免疫BALB／c小鼠，制备单克隆抗体；并对单克隆抗体的特性进行鉴定；利用纯化后的抗体建立了夹心ELISA定量检测SEC2方法，并进行了验证和初步应用。结果：筛选出4株稳定分泌抗SEC2抗体的杂交瘤细胞株，其免疫球蛋白亚类均为IgG1，除两株单抗的SEC2识别位点相同外，其余单抗均特异性识别SEC2的不同结合位点。建立的夹心ELISA定量检测法，特异性、灵敏度、重复性均较好，检测SEC2范围为0．5—20ng,／ml，回收率在97．8％-101％，变异系数为2％-5％。结论：本研究制备的抗SEC2的单克隆抗体，可用于建立了SEC2定量检测方法，为控制金葡素制品质量和金葡菌肠毒素研究提供了较实用的方法。     

抗人IgG单克隆抗体的研究 Ⅲ.8株杂交瘤细胞分泌的单克隆抗体特性分析和初步应用

本文报道8株杂交瘤细胞分泌的单克隆抗体的血清学特性,其中4种属抗全IgG,3种是对IgG_4无反应的抗IgG,1种是对IgG_3无反应的抗IgG。各单克隆抗体之间的效价和结合抗原的能力有所差异。根据组合试验,选出A_2与B_1二种单克隆抗体进行组合,用以检测正常人血清中IgG含量,与常规抗血清相比较呈良好的相关性(r=0.90)。用以制备亲和层析柱,纯化人IgG,得率比常规抗血清高7.3倍。据此认为,研制这类单克隆抗体将为临床免疫检测提供有效的试剂。     

Modulation of M(2) muscarinic receptor-receptor interaction by immunoglobulin G antibodies from Chagas' disease patients

Circulating immunoglobulin (Ig)G antibodies against M(2) muscarinic acetylcholine receptors (M(2) mAChR) have been implicated in Chagas' disease (ChD) pathophysiology. These antibodies bind to and activate their target receptor, displaying agonist-like activity through an unclear mechanism. This study tested the ability of serum anti-M(2) mAChR antibodies from chronic ChD patients to modulate M(2) muscarinic receptor-receptor interaction by bioluminescence resonance energy transfer (BRET). Human embryonic kidney (HEK) 293 cells co-expressing fusion proteins M(2) mAChR-Renilla luciferase (RLuc) and M(2) mAChR-yellow fluorescent protein (YFP) were exposed to the serum IgG fraction from ChD patients, and BRET between RLuc and YFP was assessed by luminometry. Unlike serum IgG from healthy subjects and conventional muscarinic ligands, ChD IgG promoted a time- and concentration-dependent increase in the BRET signal. This effect neither required cellular integrity nor occurred as a consequence of receptor activation. Enhancement of M(2) receptor-receptor interaction by ChD IgG was receptor subtype-specific and mediated by the recognition of the second extracellular loop of the M(2) mAChR. The monovalent Fab fragment derived from ChD IgG was unable to reproduce the effect of the native immunoglobulin. However, addition of ChD Fab in the presence of anti-human Fab IgG restored BRET-enhancing activity. These data suggest that the modulatory effect of ChD IgG on M(2) receptor-receptor interaction results from receptor cross-linking by bivalent antibodies.     

抗人肝再生增强因子单克隆抗体的研制

目的　利用纯化的重组人肝再生增强因子(hALR)制备抗hALR的单克隆抗体,建立hALR的检测方法。方法 采用杂交瘤技术制备单克隆抗体,经ELISA和免疫印迹证明其特异性。结果获得了4株分泌抗hALR特异性抗体的杂交瘤 细胞系;无血清培养液效价为1×10-2,腹水效价为1×10-5;亚类鉴定表明2株单克隆抗体为IgGl,另2株为IgG2b;免疫印迹 显示抗体结合抗原的分子量与hALR相符,为特异性抗hALR抗体。结论通过杂交瘤技术,获得了抗hALR的单克隆抗体 为以后的工作奠定了基础。     

抗金黄色葡萄球菌C_1型肠毒素McAb的制备及初步应用

金葡菌Ｃ１型肠毒素免疫ＢＡＬＢ／ｃ小鼠，取其脾细胞与Ｓｐ２／０小鼠骨髓瘤细胞融合选出了能分泌高滴度ＭｃＡｂ的１８个克隆株，对其中１０株进行了鉴定，６株属ＩｇＧ１，４株属ＩｇＧ３。用双抗体夹心法和特异性中和抑制试验比较了ＭｃＡｂ和ＰｃＡｂ的敏感性和特异性，并用制备的ＭｃＡｂ诊断试剂对ＳＥＣＩ污染食品进行了检测应用，可特异检出ｌｕｇＳＥＣ１／０．５ｇ食物／ｍｌ。     

抗肠道病毒EV71型外壳蛋白VP1单克隆抗体的制备和鉴定

目的 制备具有中和活性的抗肠道病毒EV71型外壳蛋白VP1的单克隆抗体.方法 人工合成SP55和SP70(分别包含VP1的第163-177,208-222位氨基酸)两段VP1的多肽,分别免疫BALB/c小鼠,常规杂交瘤技术进行细胞融合,用间接酶联免疫吸附试验(ELISA)筛选阳性杂交瘤细胞并测定效价.用分泌的单抗和EV71病毒在RD细胞上进行中和试验以检验其中和活性.结果 得到2株能稳定分泌抗肠道病毒EV71型VP1蛋白单克隆抗体的杂交瘤细胞株,2株单抗的中和效价分别为1:8和1:16.结论 成功制备出2株具有中和活性的抗肠道病毒EV71型VP1蛋白单克隆抗体,为其下一步应用打下基础.     

Anti-M4 antibodies in primary biliary cirrhosis react with sulphite oxidase, an enzyme of the mitochondrial inter-membrane space.

Testing three anti-M2/anti-M4-positive and three anti-M2 positive/anti-M4-negative primary biliary cirrhosis (PBC) marker sera against different mitochondrial enzymes by ELISA it could be shown that only the anti-M4-positive sera reacted with pyruvate dehydrogenase (M2) and sulphite oxidase (SO), an enzyme of the mitochondrial inter-membrane space in parallel. Absorption of these sera with SO abolished completely the anti-M4 antibodies but had no effect on the anti-M2 activity. The specificity of this reaction was also documented by examining 30 anti-M2/anti-M4-positive sera showing that 28 of them were positive with SO. Among ten anti-M2/anti-M8-positive but anti-M4-negative PBC sera, four became positive when tested against SO, indicating a higher sensitivity of SO for the demonstration of anti-M4. Retesting sera from 76 PBC patients with defined anti-mitochondrial antibody (AMA) profiles who had been followed for up to 18 years against SO by ELISA and complement fixation test (CFT), none of 32 patients with profile A B (positive for anti-M2 and/or anti-M9 by ELISA; benign course) but 33 of 44 patients with profile C/D (anti-M2/anti-M4 and or anti-M8 positive by CFT and or ELISA; progressive course) were positive. These data indicate that sulphite oxidase can be used in the ELISA for the detection of anti-M4 antibodies which may be of prognostic relevance.     

Use of ATPase-associated antigen (M2) for detection of antimitochondrial antibodies in primary biliary cirrhosis by fluorometric immunoassay

An indirect binding assay, the fluorometric immunoassay (FIAX), was established for the detection of anti-M2 antibodies which are specific markers for primary biliary cirrhosis (PBC). Submitochondrial particles (SMP) from beef heart and rat liver and the ATPase-associated antigen (M2) were used. The antigens were fixed to a cellulose acetate surface, SMP at a concentration of 2 mg/ml, ATPase at a concentration of 0.2 mg/ml. Sera were used at 1:60 and 1:120 and bound antimitochondrial antibodies (AMA) were demonstrated by fluorescent isothiocyanate labelled monospecific anti-human IgG, IgM and IgA antibodies. The fluorescent signals were proportional to the AMA titre in the serum samples and were measured in a fluorometer (FIAX 100). Of 94 patients with PBC, 92 had AMA against SMP from beef heart compared with 76 in the complement fixation test (CFT) and 84 in the immunofluorescence test (IFL). Ninety reacted with the ATPase-associated M2 antigen. Sera from patients known to have AMA of different specificities (anti-M1, anti-M3, anti-M5, anti-M6) reacted with SMP from beef heart and/or rat liver but not with M2.     

Opsonic Antibodies to the Surface M Protein of Group A Streptococci in Pooled Normal Immunoglobulins (IVIG): Potential Impact on the Clinical Efficacy of IVIG Therapy for Severe Invasive Group A Streptococcal Infections

The surface M protein of group A streptococci (GAS) is one of the major virulence factors for this pathogen. Antibodies to the M protein can facilitate opsonophagocytosis by phagocytic cells present in human blood. We investigated whether pooled normal immunoglobulin G (IVIG) contains antibodies that can opsonize and enhance the phagocytosis of type M1 strains of GAS and whether the levels of these antibodies vary for different IVIG preparations. We focused on the presence of anti-M1 antibodies because the M1T1 serotype accounts for the majority of recent invasive GAS clinical isolates in our surveillance studies. The level of anti-M1 antibodies in three commercial IVIG preparations was determined by enzyme-linked immunosorbent assay (ELISA), and the opsonic activity of these antibodies was determined by neutrophil-mediated opsonophagocytosis of a representative M1T1 isolate. High levels of opsonic anti-M1 antibodies were found in all IVIG preparations tested, and there was a good correlation between ELISA titers and opsonophagocytic activity. However, there was no significant difference in the levels of opsonic anti-M1 antibodies among the various IVIG preparations or lots tested. Adsorption of IVIG with M1T1 bacteria removed the anti-M1 opsonic activity, while the level of anti-M3 opsonophagocytosis was unchanged. Plasma was obtained from seven patients with streptococcal toxic shock syndrome who received IVIG therapy, and the level of anti-M1 antibodies was assessed before and after IVIG administration. A significant increase in the level of type M1-specific antibodies was found in the plasma of all patients who received IVIG therapy (P < 0.006). The results reveal another potential mechanism by which IVIG can ameliorate severe invasive group A streptococcal infections.